$CELC News

Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line Therapy

Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits

Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans Transcript

Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026

Citizens Maintains Market Outperform on Celcuity, Raises Price Target to $177

Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer

HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $155

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

FDA Approves Gedatolisib With Fulvestrant, With Or Without Palbociclib, For Hr-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer

Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy - Slideshow

Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering

Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients

Reported Earlier, Celcuity Prices Upsized $500M Convertible Notes Offering (Up From Prior $400M)

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Craig-Hallum Maintains Buy on Celcuity, Lowers Price Target to $171

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

Wells Fargo Maintains Overweight on Celcuity, Lowers Price Target to $166

Celcuity: Selloff On Yesterday's Data Unwarranted; Buy Rating Upheld

HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $145